Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Cancer Genetics Inc (CGIX)

Cancer Genetics Inc (CGIX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 18,833
  • Shares Outstanding, K 4,085
  • Annual Sales, $ 7,310 K
  • Annual Income, $ -6,710 K
  • 60-Month Beta 2.72
  • Price/Sales 1.59
  • Price/Cash Flow 42.72
  • Price/Book 2.40
Trade CGIX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.10
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/18/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.30 +7.21%
on 03/30/21
7.48 -38.37%
on 03/22/21
-1.90 (-29.19%)
since 02/26/21
3-Month
2.61 +76.63%
on 12/29/20
17.50 -73.66%
on 02/10/21
+1.90 (+70.11%)
since 12/28/20
52-Week
2.11 +118.73%
on 10/30/20
17.50 -73.66%
on 02/10/21
+1.53 (+49.68%)
since 03/27/20

Most Recent Stories

More News
Vyant Bio Announces Investor Webcast to Provide Updates Post Merger between Cancer Genetics and StemoniX

Vyant Bio, Inc. (the "Company") (Nasdaq: VYNT), is a new force in drug discovery focused on integrating human-powered scientific and technology-based systems to de-risk and accelerate the discovery and...

CGIX : 4.61 (-2.33%)
VYNT : 3.71 (-7.71%)
Cancer Genetics and StemoniX Announce Merger Closing

Cancer Genetics, Inc. Renamed to Vyant Bio, Inc.

CGIX : 4.61 (-2.33%)
Cancer Genetics Announces Shareholder Approval of All Proposals in Connection with the Proposed Merger with StemoniX

Combined entity creates an innovative platform to de-risk and accelerate the discovery and development of preclinical and clinical pipelines with biopharma partners as well as the proprietary pipeline...

CGIX : 4.61 (-2.33%)
Cancer Genetics Announces Roland J. Carrillo, PhD as Vice President of Business Development

Cancer Genetics, Inc. (the "Company") (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today the appointment of Roland J. Carrillo, PhD as the Vice President of Business...

CGIX : 4.61 (-2.33%)
Cancer Genetics to Present at the Annual 33rd ROTH Conference

Cancer Genetics, Inc. (the "Company") (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay Roberts, Chief Executive Officer, will present at the Annual 33 ROTH...

CGIX : 4.61 (-2.33%)
Non-Invasive Liquid Biopsy to Help Cancer Diagnosis Gets CE Certification

LONDON, March 11, 2021 /PRNewswire/ -- Datar Cancer Genetics, a global leader in non-invasive cancer diagnostics, has receivedConformite Europeenne (CE) Mark forits innovative TruBlood solution, a new...

CGIX : 4.61 (-2.33%)
Non-Invasive Liquid Biopsy to Help Cancer Diagnosis Gets CE Certification

, /PRNewswire/ -- Datar Cancer Genetics, a global leader in non-invasive cancer diagnostics, has received Conformité Européenne (CE) Mark for its innovative TruBlood solution, a new paradigm in cancer...

CGIX : 4.61 (-2.33%)
Cancer Genetics to Present at the H.C. Wainwright Global Life Sciences Conference

Cancer Genetics, Inc. (the "Company") (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay Roberts, Chief Executive Officer, will present at H.C. Wainwright's...

CGIX : 4.61 (-2.33%)
Hematologic Malignancies Testing Market Size Worth USD 5.45 Billion by 2027 | Increasing Research and Development Activities and Increasing Prevalence of Cancer are Significant Factors Influencing Industry Growth, says Emergen Research

The global Hematologic Malignancies Testing Market is forecasted to be worth USD 5.45 Billion by 2027, according to a current analysis by Emergen Research. Due to the increasing prevalence of cancer, the...

ABT : 121.04 (+0.12%)
CGIX : 4.61 (-2.33%)
NVTA : 37.61 (-1.03%)
SSMXY : 51.1400 (+0.08%)
Cancer Genetics Announces Closing of $17.5 Million Common Stock Offering Priced At-the-Market under Nasdaq Rules

Cancer Genetics, Inc. (the "Company") (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced the closing of its previously announced registered...

CGIX : 4.61 (-2.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Cancer Genetics, Inc. operates as a diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve the diagnosis, prognosis and response to treatment of cancer. The company's tests target cancers, including hematological, urogenital, and HPV-associated...

See More

Key Turning Points

3rd Resistance Point 5.16
2nd Resistance Point 4.92
1st Resistance Point 4.77
Last Price 4.61
1st Support Level 4.38
2nd Support Level 4.14
3rd Support Level 3.99

See More

52-Week High 17.50
Fibonacci 61.8% 11.62
Fibonacci 50% 9.80
Fibonacci 38.2% 7.99
Last Price 4.61
52-Week Low 2.11

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar